Results 131 to 140 of about 1,206,341 (327)

Autoantigen mRNA‐LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity

open access: yesAdvanced Science, EarlyView.
Systemic and intramuscular delivery of autoantigen mRNA via lipid nanoparticles reprograms antigen‐presenting cells toward a mature, homeostatic state, driving antigen‐specific T cell exhaustion and providing therapeutic efficacy across autoimmune disease models.
Paulien Baeten   +30 more
wiley   +1 more source

Targeting p21‐High Senescent Kupffer Cells Nanotherapeutically Potentiates Antitumor Immunity in Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

open access: yesAdvanced Science, EarlyView.
Schematic illustration of a biomimetic SKEV@AAV platform targeting p21‐high senescent Kupffer cells (sKCs) in hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). p21‐high sKCs accumulate in the PVTT microenvironment and establish an immunosuppressive, SASP‐rich environment that facilitates tumor cell proliferation and immune evasion.
Na Ta   +10 more
wiley   +1 more source

Effect of Flight in Mission SL-3 on Interferon-Gamma Production by Rats

open access: green
Adrian Co-Investigator: Mandel   +3 more
openalex   +1 more source

A comparative performance evaluation of the VIDAS cytomegalovirus (CMV) interferon-gamma release assay (IGRA) and T-SPOT CMV for measuring CMV-specific T-cell responses in allogeneic hematopoietic stem cell transplant recipients receiving letermovir prophylaxis [PDF]

open access: diamond
Carlos Solano de la Asunción   +14 more
openalex   +1 more source

A Pancreatitis‐Inspired Trypsinogen Nanoplatform Reprograms Tumor‐Associated Macrophages via NF‐κB for Pancreatic Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
Trypsinogen‐loaded nanoparticles reprogram TAMs via NF‐κB/NLRP3, driving M2→M1 conversion and potent phagocytosis to unleash antitumor immunity. ABSTRACT Although reprogramming tumor‐associated macrophages (TAMs) represents a promising therapeutic strategy, approaches that are both precise and safe remain scarce.
Lei Cao   +7 more
wiley   +1 more source

Interferon-gamma autoantibodies in patients with infectious uveitis: a pilot case-control study. [PDF]

open access: yesBMC Infect Dis
Opasatian A   +4 more
europepmc   +1 more source

Comparative Agreement of Intradermal Tuberculin Test and Interferon-Gamma Release Assay in Bovine Tuberculosis Surveillance in Sicily, Italy (2024–2025)

open access: gold
Delia Gambino   +10 more
openalex   +1 more source

EpCAM+ Extracellular Vesicle PD‐L1 Dynamics as a Predictive Biomarker of Immune Checkpoint Blockade Response

open access: yesAdvanced Science, EarlyView.
A highly sensitive SERS‐based platform measures PD‐L1 expression on EpCAM+ circulating EVs from cancer patients undergoing immunotherapy. Monitoring dynamic changes after treatment reveals that reduced EpCAM+ EV PD‐L1 levels associate with improved long‐term clinical outcomes, establishing a non‐invasive approach for tracking immune checkpoint ...
Byeonggeol Mun   +15 more
wiley   +1 more source

The GBP5 protein detection in tuberculosis antigen-stimulated blood and its comparison with interferon-gamma release assay

open access: gold
Ze-Feng Li   +10 more
openalex   +1 more source

Home - About - Disclaimer - Privacy